KPC Pharmaceuticals,Inc. (SHA:600422)
China · Delayed Price · Currency is CNY 9.50
+0.01 (0.11%)
Apr 29, 2026, 3:00 PM CST
KPC Pharmaceuticals,Inc. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 117.67 | 349.94 | 648.08 | 540.71 | 383.18 | 507.67 |
Depreciation & Amortization | 185.62 | 185.62 | 199.11 | 209.3 | 208.8 | 183.8 |
Other Amortization | 15.21 | 15.21 | 10.34 | 11.58 | 35.58 | 13.9 |
Loss (Gain) From Sale of Assets | -0.67 | -0.67 | -1.01 | -1.04 | -15.21 | -2.2 |
Asset Writedown & Restructuring Costs | 13.26 | 13.26 | 1.61 | 30.55 | 57.73 | 0.29 |
Loss (Gain) From Sale of Investments | -170.92 | -170.92 | -21.85 | -18.34 | -16.66 | -149.69 |
Stock-Based Compensation | - | - | - | -1.07 | - | - |
Provision & Write-off of Bad Debts | 4.39 | 4.39 | 45.03 | 44.11 | 39.67 | 35.44 |
Other Operating Activities | -85.39 | 156.59 | 148.77 | 159.76 | 54.61 | 57.98 |
Change in Accounts Receivable | 345.14 | 345.14 | 41.82 | -18.64 | -533.42 | -356.22 |
Change in Inventory | 149.98 | 149.98 | 271.85 | 44.53 | 202.88 | -185.94 |
Change in Accounts Payable | -801.27 | -801.27 | -543.89 | -241.15 | -146.74 | 140.83 |
Change in Other Net Operating Assets | - | - | - | - | - | 5.85 |
Operating Cash Flow | -185.01 | 289.24 | 808.07 | 754.33 | 253.9 | 251.63 |
Operating Cash Flow Growth | - | -64.21% | 7.12% | 197.10% | 0.90% | -38.62% |
Capital Expenditures | -109.61 | -90.56 | -79.43 | -109.64 | -101.75 | -236.17 |
Sale of Property, Plant & Equipment | 1.13 | 1.78 | 0.05 | 8.53 | 36.23 | 9.99 |
Divestitures | 4.1 | 4.1 | - | 1.35 | 5.24 | 10.13 |
Investment in Securities | 450.05 | -582.36 | 149.81 | -241.06 | -183.3 | 208.71 |
Other Investing Activities | 30.79 | 30.03 | 15.6 | 15.29 | 8.96 | 26.72 |
Investing Cash Flow | 376.47 | -637 | 86.03 | -325.53 | -234.6 | 19.38 |
Short-Term Debt Issued | - | - | 2,098 | 2,043 | 7.92 | - |
Long-Term Debt Issued | - | 1,740 | 777.42 | 971.04 | 1,199 | 905 |
Total Debt Issued | 1,028 | 1,740 | 2,876 | 3,014 | 1,207 | 905 |
Short-Term Debt Repaid | - | - | -1,407 | -2,145 | -12.01 | - |
Long-Term Debt Repaid | - | -877.08 | -871.3 | -1,025 | -895.57 | -903.47 |
Total Debt Repaid | -1,105 | -877.08 | -2,279 | -3,170 | -907.58 | -903.47 |
Net Debt Issued (Repaid) | -76.85 | 863.13 | 597.24 | -156.52 | 299.04 | 1.52 |
Issuance of Common Stock | - | - | - | - | - | 10.65 |
Repurchase of Common Stock | - | - | -2.21 | -2.16 | -0.38 | - |
Common Dividends Paid | -279.09 | -280.06 | -172.54 | -146.6 | -231.34 | -203.57 |
Other Financing Activities | -521.45 | -1,238 | -550.48 | -307.62 | 0.49 | -28.04 |
Financing Cash Flow | -877.39 | -654.64 | -127.99 | -612.9 | 67.8 | -219.45 |
Foreign Exchange Rate Adjustments | -2.4 | -0.53 | 0.99 | 1.74 | 2.75 | -2.75 |
Net Cash Flow | -688.34 | -1,003 | 767.09 | -182.35 | 89.84 | 48.81 |
Free Cash Flow | -294.61 | 198.68 | 728.63 | 644.69 | 152.15 | 15.46 |
Free Cash Flow Growth | - | -72.73% | 13.02% | 323.72% | 884.44% | -93.85% |
Free Cash Flow Margin | -5.08% | 3.02% | 8.67% | 7.65% | 1.84% | 0.19% |
Free Cash Flow Per Share | -0.39 | 0.26 | 0.97 | 0.85 | 0.20 | 0.02 |
Cash Income Tax Paid | 504.82 | 551.12 | 733.31 | 759.72 | 620.24 | 479.56 |
Levered Free Cash Flow | -841.85 | -1,191 | 2,487 | -462.29 | 174.5 | -194.49 |
Unlevered Free Cash Flow | -810.23 | -1,160 | 2,504 | -448.79 | 199.95 | -173.5 |
Change in Working Capital | -264.18 | -264.18 | -222.01 | -221.22 | -493.82 | -395.56 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.